<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Hematology Am Soc Hematol Educ Program</journal-id>
<journal-id journal-id-type="iso-abbrev">Hematology Am Soc Hematol Educ Program</journal-id>
<journal-id journal-id-type="hwp">bloodbook</journal-id>
<journal-id journal-id-type="publisher-id">bloodbook</journal-id>
<journal-title-group>
<journal-title>Hematology: the American Society of Hematology Education Program</journal-title>
</journal-title-group>
<issn pub-type="ppub">1520-4391</issn>
<issn pub-type="epub">1520-4383</issn>
<publisher>
<publisher-name>American Society of Hematology</publisher-name>
<publisher-loc>Washington, DC</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27913494</article-id>
<article-id pub-id-type="pmc">6142512</article-id>
<article-id pub-id-type="publisher-id">088422</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Genetic Susceptibility to Leukemias</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Introduction to cancer genetic susceptibility syndromes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>McGee</surname>
<given-names>Rose B.</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Nichols</surname>
<given-names>Kim E.</given-names>
</name>
</contrib>
<aff>Division of Cancer Predisposition, St. Jude Children’s Research Hospital, Memphis, TN</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><bold>Correspondence</bold> Kim E. Nichols, Division of Cancer Predisposition, St. Jude Children’s Research Hospital, Memphis, TN 38105; e-mail: <email>kim.nichols@stjude.org</email>.</corresp>
<fn fn-type="COI-statement">
<p>Conflict-of-interest disclosures: The authors declare no competing financial interests.</p>
</fn>
<fn fn-type="other">
<p>Off-label drug use: None disclosed.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>2</day>
<month>12</month>
<year>2016</year>
</pub-date>
<volume>2016</volume>
<issue>1</issue>
<fpage>293</fpage>
<lpage>301</lpage>
<permissions>
<copyright-statement>© 2016 by The American Society of Hematology. All rights reserved.</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>American Society of Hematology</copyright-holder>
</permissions>
<self-uri xlink:href="bloodbook-2016-293.pdf" xlink:title="pdf"></self-uri>
<abstract>
<p>The last 30 years have witnessed tremendous advances in our understanding of the cancer genetic susceptibility syndromes, including those that predispose to hematopoietic malignancies. The identification and characterization of families affected by these syndromes is enhancing our knowledge of the oncologic and nononcologic manifestations associated with predisposing germ line mutations and providing insights into the underlying disease mechanisms. Here, we provide an overview of the cancer genetic susceptibility syndromes, focusing on aspects relevant to the evaluation of patients with leukemia and lymphoma. Guidance is provided to facilitate recognition of these syndromes by hematologists/oncologists, including descriptions of the family history features, tumor genotype, and physical or developmental findings that should raise concern for an underlying cancer genetic syndrome. The clinical implications and management challenges associated with cancer susceptibility syndromes are also discussed.</p>
</abstract>
<counts>
<page-count count="9"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>